[Federal Register: April 12, 2001 (Volume 66, Number 71)]
[Notices]
[Page 18967-18968]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12ap01-76]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Vector Systems for the Generation of Adeno-Associated Virus
Particles
JA Chiorini, R Kotin, B Safer, E Urcelay (NHLBI)
Serial No. 08/157,740 filed 24 Nov 1993, now US Patent 5,693,531 issued
02 Dec 1997
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail:
ruckers@od.nih.gov
This patent relates to a system for the production of recombinant
AAV vectors for gene therapy. More particularly, the patent relates to
an AAV vector system which utilizes an inducible system for the
production of high titer virus. The first vector contains a 5' and 3'
AAV ITR flanking the heterologous gene of interest to be delivered. The
second vector contains an inducible origin of replication and the AAV
rep and cap proteins. This second vector provides a means for
increasing the amount of AAV structural proteins available for the
production of infectious AAV particles. In the presence of the inducing
agent these two vector are able to produce high titer of infectious AAV
particles which can be used to deliver the heterologous gene of
interest.
This work has been published, in part, at Chiorini, JA, et al.
``High-efficiency transfer of the T cell co-stimulatory molecule B72 to
lymphoid cells using high-titer recombinant adeno-associated virus
vectors'' Hum Gene Ther 6(12):1531-41 (Dec 1995).
Immunization from an Immunized Allogeneic Bone Marrow Donor
Larry W. Kwak, Dan L. Longo (NCI)
Serial No. 08/153,464 filed 17 Nov 1993; U.S. Patent 5,861,158 issued
19 Jan 1999
Licensing Contact: Elaine White; 301/496-7056 ext. 282; e-mail:
gesee@od.nih.gov
A novel method has been developed for transferring immunity against
specific types of tumors from a bone marrow donor to a recipient.
Although there have been major advances in studying the biology of B-
cell and leukemia cancers in recent years, progress in the treatment of
such diseases has been modest since the treatment of alkylating agents
more than 30 years ago. An approach using intensive, high-dose
chemoradiotherapy combined with bone marrow transplantation (to help
improve tolerance of bone marrow cells to intense therapy) is presently
being explored by several groups of investigators. However, although
this type of therapy has improved initial responsive rates, the vast
majority of patients (90 percent) eventually relapse.
The current invention provides a method of improving a
transplantation of hematopoietic cells from a donor to a recipient to
treat a hematopoietic cell tumor in the recipient comprising immunizing
the donor's hematopoietic cells with an antigen specific for the
recipient's hematopoietic cell tumor, and transplanting the donor's
immunized hematopoietic cells to the recipient. This method offers a
novel means for conferring immunity against, and thereby treating, B-
cell and leukemia cancers as well as other types of cancers.
A Murine Melanoma Transduced with CCR7 as a Model of Enhanced
Metastasis to Lymph Nodes
Sam T. Hwang (NCI)
DHHS Reference No. E-104-01/0
Licensing Contact: Elaine White; 301/496-7056 ext. 282; e-mail:
gesee@od.nih.gov
The current invention embodies a B16 murine melanoma cell line
which has been stably transduced with the gene for CCR7, a gene which
promotes the migration of activated dendritic cells into lymphatic
vessels. This transduced cell line has been shown to metastasize much
more efficiently to lymph nodes than non-transduced cells. While the
spontaneous rate of metastasis to lymph nodes is quite low for non-
transduced B16 cells, the inventor has found 200--1400 times more
melanoma-specific mRNA in the lymph nodes of mice which have been
injected with the CCR7-expressing melanoma cells. As melanoma in humans
first metastasizes by invading the lymphatics and migrating to the
draining lymph nodes, the transduced B16 cell line embodied in this
invention appears to represent a
[[Page 18968]]
valuable model system for identification and testing of agents to be
used in prevention or reduction of melanoma metastasis via a lymphatic
route. The cell line is available for licensing via Biological
Materials License Agreements.
Dated: April 3, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 01-9013 Filed 4-11-01; 8:45 am]
BILLING CODE 4140-01-P